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Mycobacterium tuberculosis (Mtb) remains a major challenge to global health, made 2 
worse by the spread of multi-drug resistance. Currently, the efficacy and safety of 3 
treatment is limited by difficulties in achieving and sustaining adequate tissue antibiotic 4 
concentrations while limiting systemic drug exposure to tolerable levels. Here we show 5 
that nanoparticles generated from a polymer-antibiotic conjugate (‘nanobiotics’) deliver 6 
sustained release of active drug upon hydrolysis in acidic environments, found within 7 
Mtb-infected macrophages and granulomas, and can, by encapsulation of a second 8 
antibiotic, provide a mechanism of synchronous drug delivery. Nanobiotics are avidly 9 
taken up by infected macrophages, enhance killing of intracellular Mtb, and are efficiently 10 
delivered to granulomas and extracellular mycobacterial cords in vivo in an infected 11 
zebrafish model. We demonstrate that isoniazid (INH)-derived nanobiotics, alone or with 12 
additional encapsulation of clofazimine (CFZ), enhance killing of mycobacteria in vitro 13 
and in infected zebrafish, supporting the use of nanobiotics for Mtb therapy and indicating 14 
that nanoparticles generated from polymer-small molecule conjugates might provide a 15 
more general solution to delivering co-ordinated combination chemotherapy.  16 
 17 
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1. Introduction 1 
Over 1.6 million deaths annually are caused by Mtb infection [1]. Existing antibiotic 2 
regimens for Mtb infection require long durations of therapy with multiple drugs and are 3 
associated with significant side effects (due to systemic exposure), contributing to poor 4 
adherence and treatment failure [2].  5 
One of the major difficulties in treating tuberculosis is that Mtb can survive both 6 
intracellularly within macrophages and extracellularly within granulomas; environments 7 
where conventional drug delivery is compromised. Bacteria are therefore exposed to 8 
sub-lethal concentrations of antibiotics, permitting firstly the development of phenotypic 9 
drug tolerance and eventually the acquisition of drug resistance mutations [2]. 10 
Due to the scarcity of new drugs against Mtb and thus limited therapeutic options for 11 
drug-resistant Mtb, increased efforts have been put on the development of improved 12 
formulations and delivery systems for existing antibiotic regimens [3].  13 
In the last two decades, the application of polymer-drug conjugation to drug delivery has 14 
increased noticeably, offering advantages including enhanced drug solubilization, 15 
reduced immunogenicity, controlled delivery, increased efficacy, and improved 16 
pharmacokinetics. However, most polymer-small molecule drug conjugates have to date 17 
used non-biodegradable polymer carriers, such as polyethylene glycol (PEG), that 18 
constrains polymer size below the molecular cut-off of ~40 kDa required for renal 19 
elimination [4].  Alternatively, hydrolysable hydrophobic polyesters, such as 20 
polycaprolactone (PCL) and poly(lactide-co-glycolide) (PLGA), widely employed in FDA-21 
approved devices, present limited functionality for drug conjugation [5] and are used to 22 
physically entrap drugs within nanoparticulate carriers [6]. However, many anti-23 
tuberculosis drugs are highly water soluble, making them easily leached out from the 24 
nanocarriers during fabrication and more prone to burst release in systemic circulation 25 
[7-10]. Polyketals, which in contrast with polyesters yield pH neutral hydrolysis products, 26 
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have also recently been explored as new class of acid responsive and biodegradable 1 
polymers suitable for drug conjugation [11].  2 
Isoniazid (INH) is a potent antibiotic universally used as a first-line treatment of 3 
tuberculosis, either as part of combination therapy to treat the active disease, or often 4 
used as monotherapy in cases of latent tuberculosis infection. Despite its high activity 5 
against Mtb, INH is rapidly egested and highly toxic, prompting the development of 6 
delivery systems aiming for targeted and controlled release of INH [12, 13]. A few 7 
polymers have been explored for INH conjugation, including natural polymers, such as 8 
gelatin [14] and chitosan [13], and synthetic polymers, such as PLGA [15]. However, 9 
these systems involve further chemical modifications of the polymers in order to 10 
introduce functional groups amenable for drug conjugation. Berezin and Skorik prepared 11 
chitosan-INH conjugates using two different synthetic routes, either by modifying 12 
chitosan with acrylic acid or epichlorohydrin, before INH conjugation. Modified chitosan 13 
polymers presented lower biodegradability, and either similar (for N-(2-14 
carboxyethyl)chitosan INH conjugates) or higher (for N-(3-chloro-2-15 
hydroxypropyl)chitosan INH conjugates)  minimum inhibitory concentrations compared 16 
to free drug, possibly due to incomplete cleavage of INH from the polymer [13].  In a 17 
different study, Huang and co-workers used an INH conjugated star PLGA to fabricate a 18 
composite scaffold with β-tricalcium phosphate to treat bone tuberculosis. The process 19 
involved esterification of the PLGA and 4-carboxybenzaldehyde prior to drug 20 
conjugation. They have produced a 4-arm PLGA-INH conjugate instead of a linear 21 
polymer in order to achieve suitable drug loading capacity [15].  22 
Another important aspect for combination therapy is the ability to co-deliver multiple 23 
drugs to the target sites. Manca and co-workers prepared microparticles of gelatin-INH 24 
conjugates with encapsulated rifampicin by spray drying technique. INH-derivatized 25 
gelatin was prepared by heterogenous reaction of amidation, yielding an amide bond 26 
between the terminal acyl chloride group of gelatine and the hydrazide group of INH. 27 
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They have shown good nebulization efficiency, cell internalization, and low cytotoxicity, 1 
but they have not reported the therapeutic efficacy of the conjugates [14].     2 
 As a response to these challenges, we have developed a polymeric nanoparticulate 3 
drug delivery system, using simple, fast and scalable processes, where antibiotics are 4 
covalently incorporated into a polymer chain, through a hydrolysable bond, creating 5 
‘nanobiotics’.  6 
Multiple copies of antibiotics can be incorporated into the polymer chain, which becomes 7 
active upon pH-triggered hydrolysis to achieve targeted release of a high drug payload. 8 
As a proof-of-concept, we incorporated isoniazid (INH) by reacting its hydrazide group 9 
with the ketone group of an α-keto polyester (Fig. 1). However, this strategy also allows 10 
for the incorporation of other polar antibiotics, such as the first line drug ethambutol or 11 
AZD5847 - a next generation oxazolidinone currently in Phase II clinical trials [16], which 12 
could be used as the polyol monomer instead of 1,8-octanediol. On the other hand, 13 
hydrophobic antibiotics, with poor water solubility and poor caseum penetration [17], can 14 
be easily encapsulated in these systems, providing a mechanism of synchronous 15 
nanoscale delivery of hydrophilic and hydrophobic payloads, while preventing 16 
undesirable drug-drug interactions. 17 
Nanobiotics could be an invaluable tool for delivering drugs in a spatiotemporal-18 
controlled manner, increasing the bioavailability of drugs in the target tissue, while 19 
simultaneously protecting drugs against degradation and minimizing their toxic effects in 20 




Fig. 1. Synthesis of an α-keto polyester by (trans)esterification reaction catalysed by 2 
CALB and conjugation to isoniazid (INH).   3 
 4 
2. Materials and methods 5 
 6 
2.1. Chemicals 7 
All reagents were analytical grade. 1,8-Octanediol, calcium pantothenate, citric acid, 8 
chloroform, clofazimine (CFZ), coumarin 6 (Cou-6), dimethyl 2-oxoglutarate, dimethyl 9 
sulfoxide (DMSO) anhydrous, diphenyl ether, Dulbecco’s Modified Eagle’s Medium - 10 
high glucose (DMEM), hexane, L-leucine, poly(vinyl alcohol) (PVA; Mw 31,000−50,000; 11 
98-99% hydrolysed), phosphate buffered saline tablets, phenol red, phorbol 12-myristate 12 
13-acetate (PMA), silicon oil, sodium phosphate dibasic, Tween 80 and tricaine were 13 
purchased from Sigma-Aldrich, Merck (UK). Dichloromethane, formaldehyde, 14 
hygromycin B, methanol, Middlebrook 7H9 with OADC, Remel Middlebrook 7H10 Agar 15 
(Dehydrated) and trifluoroacetic acid (TFA) were acquired from Thermo Fisher Scientific 16 
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(UK). Dimethyl sulphoxide-[D₆] (99.8% D), fetal calf serum (FCS; Sera Plus, EU 1 
approved regions, special processed FBS, 0.2 µm sterile filtered) and macrophage 2 
colony stimulating factor (MCSF) were purchased from VWR (UK), PanBiotech 3 
(Germany) and Peprotech (UK), respectively. 4 
 5 
2.2. Antibodies 6 
The following antibodies were used for flow cytometric studies: Brilliant Violet 785™ anti-7 
human CD3 Antibody (Biolegend®, clone OKT3, 317330), CD14 Monoclonal Antibody 8 
APC-eFluor 780 (eBioscience™, clone 61D3, 47-0149-42), PE/Cy7 anti-human CD15 9 
(SSEA-1) antibody (Biolegend®, clone W6D3, 323029), CD19 Monoclonal Antibody PE 10 
(eBioscience™, clone HIB19, 12-0199-42). The following isotype controls were used: 11 
Mouse IgG1 kappa Isotype Control, APC-eFluor 780 (eBioscience™, clone P3.6.2.8.1, 12 
47-4714-82), Brilliant Violet 785™ Mouse IgG2a, κ Isotype Ctrl Antibody (Biolegend®, 13 
MOPC-173, 400273), PE/Cy7 Mouse IgG1, κ Isotype Ctrl Antibody (Biolegend®, MOPC-14 
21, 400125), Mouse IgG1 kappa Isotype Control, PE (eBioscience™, clone P3.6.2.8.1, 15 
12-4714-81). All antibodies were used at 1/250 dilution. 16 
 17 
2.3. Blank and INH polymer synthesis 18 
1,8-Octanediol was melted in a round bottom flask at 75°C using a silicon oil bath. 19 
Dimethyl 2-oxoglutarate (1:1 M ratio to 1,8-octanediol) and Lipase acrylic resin from 20 
Candida antarctica (CALB beads; ≥5,000 U/g) (10% (w/w) relative to monomers) were 21 
added to the flask and the reaction was left for 1h at 75°C under vacuum with agitation. 22 
Temperature was increased to 90°C, diphenyl ether (3× volume of monomer) was added 23 
and reaction was incubated for another 5h. After the reaction mixture cooled to room 24 
temperature, chloroform (4× volume of monomer) was added to the flask, and the 25 
solution was filtered to remove the CALB beads. The crude solution was then 26 
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precipitated into a 20-fold excess of hexane to remove unreacted monomer. Precipitation 1 
was repeated twice, and the obtained copolymer was dried under vacuum overnight. A 2 
number average molecular weight (Mn) of 5,265 ± 487 g/mol and a dispersity (Ð) of 2.247 3 
± 0.395 (average of three different polymer batches) were determined for the synthesized 4 
polymer (blank polymer) by gel permeation chromatography (Agilent 1260 Infinity II 5 
GPC/SEC system). Briefly, a sample of blank polymer was dissolved in chloroform, 0.22 6 
µm-filtered and injected (50 µL) into a PLgel MiniMIX-B column (Agilent). Chloroform 7 
was used as eluent at a flow rate of 0.3 mL/min in a 30 min run at 25°C. The column was 8 
calibrated using polystyrene standards (Agilent). 9 
Blank polymer was dissolved in anhydrous DMSO to a final concentration of 200 mg/mL, 10 
INH (2 M equivalents excess of keto groups in the polymer) was added and the mixture 11 
was kept at 37°C with orbital agitation for 72h. After that time, the bright yellow INH-12 
functionalized polymeric solution was added dropwise to methanol (1:10 (v/v)) and 13 
subsequently poured into distilled deionised (dd) water (1:2.5 (v/v)) to remove any 14 
unreacted INH. The sample was then centrifuged for 1.5 h at 8000 rpm, supernatant was 15 
discarded and the polymeric pellet (INH Polymer) was dried overnight under vacuum.  16 
 17 
2.4. Polymer characterization by Fourier-transform infrared spectroscopy 18 
(FTIR) 19 
The chemical fingerprints of INH, blank polymer and INH polymer were determined by 20 
FTIR (PerkinElmer Spotlight 400 Frontier FT-IR equipped with Universal ATR) with a 21 
scan range of 650-4000 cm−1. Data analysis was performed in PerkinElmer Spectrum 22 
10.5.3. 23 
 24 
2.5. Polymer characterization by 1H-NMR 25 
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Polymers were dissolved in deuterated DMSO at ∼5 mg/mL concentration. A Bruker 1 
Avance III HD 500 MHz equipped with 1H/13C dual cryoprobe was used to conduct 2 
1HNMR measurements. A 10,000 Hz sweep width was observed, acquired using a digital 3 
resolution of 64K points over 3.28 s. A 30° pulse angle was used; based on a 10.5 µs, 4 
14 W pulse at 500.053 MHz being the nominal 90° pulse. 32 scans were accumulated; 5 
with an interpulse delay (D1) of 1 s. Data were analysed using Mnova NMR software 6 
(Mestrelab Research). 7 
 8 
2.6. Formulation of nanobiotics 9 
The polymer (either blank polymer or INH polymer) was dissolved in 2 mL of 10 
dichloromethane to a final concentration of 10 mg/mL. The polymer solution was added 11 
dropwise to 10× volume of an aqueous solution of 1% (w/v) PVA and homogenised for 12 
10 min at 30,000 rpm (VWR Homogenizer VDI12). The emulsion was then probe 13 
sonicated for 3 min (35% Amplitude; Pulse: 3 s ON, 6 s OFF), and stirred overnight at 14 
room temperature to evaporate dichloromethane. Finally, the sample was centrifuged for 15 
30 min at 8000 rpm and pellet was washed with and resuspended in dd water. For 16 
nanobiotics containing CFZ or Cou-6, the compounds were first solubilized in the INH 17 
Polymer solution to a final concentration of 5 mg/mL and 0.1 mg/mL of each compound, 18 
respectively, and procedure was followed as described above. INH loading was 19 
determined by high-performance liquid chromatography (Agilent 1260 Infinity II LC 20 
system). Briefly, a sample of nanobiotics was diluted in 1% TFA (v/v) (1:5 or 1:10) and 21 
incubated for 48h at 37°C, the sample was then centrifuged for 10 min at 14,000 rpm 22 
and injected (20 µL) into a Zorbax 300SB C18 column (Agilent). Samples were run for 23 
10 min at 25°C and flow rate of 0.9 mL/min using an isocratic gradient (0.1% TFA). 24 
Absorbance was followed at 260 nm and solutions of known concentrations of free INH 25 
were used for calibration. Data analysis was performed using OpenLAB CDS 26 
ChemStation for LC 1.15.26 (Agilent). CFZ loading was determined by solubilising the 27 
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nanobiotics in DMSO and measuring the absorbance at 450 nm in a microplate reader. 1 
Solutions of known concentrations of free CFZ were used for calibration.  2 
 3 
2.7. Nanobiotics characterization by Dynamic Light Scattering (DLS) and 4 
Electrophoretic Light Scattering (ELS) 5 
The hydrodynamic size and zeta potential of the nanobiotics were measured by DLS and 6 
ELS, respectively, with a Zetasizer Nano ZS system (Malvern Panalytical) fitted with a 4 7 
mW He-Ne laser operating at 633nm. Measurements were performed at 25°C and 173° 8 
angle at a final nanobiotic concentration of 0.05 mg/mL in dd water. Data were analysed 9 
using Zetasizer Software 7.13 (Malvern Panalytical).  10 
 11 
2.8. Cryo-electron microscopy (Cryo-EM) 12 
All samples were vitrified with a Thermo Fisher Vitrobot MkIV by plunge freezing in liquid 13 
ethane. The Vitrobot blot force was calibrated to give a "wedge" of thick ice on roughly 14 
1/3 of the grid, with a gradient of ice thicknesses on the other 2/3 of the grid, 15 
corresponding to a setting of "-6" on this system. Other Vitrobot conditions are: 16 
temperature 4°C, RH 100%, blot time 2.5 s, and volume of sample applied 2.5 µL. 17 
Quantifoil R1.2/1.3 300 mesh grids were used and made hydrophilic by glow discharge 18 
in a weak vacuum in a Pelco Easiglo glow discharge unit at 0.39 mbar for 60 s at 25 mA. 19 
Images were acquired on a Thermo Fisher Krios G2 with the single particle data 20 
acquisition package EPU (1.10) on a Falcon 3 direct detector at magnifications of 21 
37,000× (2.26 Å/pixel), 47,000× (1.77 Å /pixel), and 6,500× (24.7 Å /pixel). Tomography 22 
tilt series +/- 60 deg were acquired with Tomography 4 software on a Falcon 3 detector 23 
in counting mode at a nominal magnification of 37000× corresponding to a total 24 
accumulated dose of ~100 e−/Å2. Tilt series were aligned by cross-correlation with a 25 
stretching factor for tilt and reconstructed by 10 iterations of a Simultaneous Iterative 26 
Reconstruction Technique (SIRT) algorithm in Thermo Fisher Inspect 3D 4.3. 27 




2.9. In vitro release of INH at different pH  2 
Nano INH were resuspended in 3 different buffers: PBS pH 7.4, citrate-phosphate pH 6 3 
and citrate-phosphate pH 5. The resuspended nanobiotics were aliquoted (100 µL 4 
volume; 1.5 mM initial INH concentration) in triplicates and incubated at 37 °C under mild 5 
agitation. At pre-defined time intervals, nanobiotic suspensions were centrifuged at 6 
14,000 rpm for 15 min. Supernatant (80 µL) was collected and analysed for drug content 7 
by HPLC as described above. Fresh buffer (80 µL) was added and the nanobiotics were 8 
resuspended and incubated for another time interval. 9 
 10 
2.10. Flow cytometry study of nanobiotic uptake by peripheral blood cells 11 
Peripheral blood from healthy volunteers (Regional Ethics approval: REC: 14/EE/1187 12 
IRAS: 161095) was centrifuged at 500 g and 21°C for 10 min. The supernatant (plasma) 13 
was discarded and the pellet was resuspended and incubated at 37°C for 30 min. Nano 14 
INH Cou-6 were added to the cells (to a nanobiotic final concentration of 0.05 mg/mL) 15 
and the mixture was incubated at 37°C for 30 min, followed by 15 min at 4°C. Clinical 16 
grade polyclonal human IgG (Vivaglobin ®) was added to the cells and incubated at 4°C 17 
for 5 min to block Fc receptors. Cells were stained with the antibodies above for 30 min 18 
at 4°C. Red blood cells were lysed using BD FACS™ lysing solution (BD Biosciences), 19 
fixed with BD Cell Fix and transferred to CorningTM FalconTM test tube with cell strainer 20 
snap cap. Samples were analysed using an BD LSRFortessa™ cell analyzer (BD 21 
Biosciences). Data were processed using FlowJo® 10.5.0 software (FlowJo LLC). 22 
 23 
2.11. In vitro mycobacterial infection assays 24 
Primary monocyte-derived human macrophages, generated as described [18], from 25 
healthy consented subjects (Regional Ethics approval: REC: 14/EE/1187 IRAS: 26 
161095), or THP-1 cells (ATCC) were differentiated by treatment with either 100 ng/mL 27 
MCSF or 5 ng/mL PMA 48 h before infection, inoculated with M. tuberculosis H37Rv 28 
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ΔleuD ΔpanCD (Bleupan) [19], grown as described [20], using  a multiplicity of infection 1 
(MOI) of 10:1 for 2 h at 37 °C, washed with PBS, and incubated with either DMEM media, 2 
supplemented with 10% FCS, 0.4% L-leucine, 0.1% calcium pantothenate (untreated 3 
control), Nano Blank in media (negative control), INH in media (positive control) or Nano 4 
INH in media for 48 h at 37 °C. Two drug concentrations were tested: 10 µM and 100 5 
µM. Cells were lysed by osmotic shock and intracellular bacteria were counted. In case 6 
of primary monocyte-derived human macrophages, cells were lysed and plated to count 7 
colony-forming units (CFUs). In the case of THP-1 cells, a validated luminescent reporter 8 
strain of M. tuberculosis H37Rv ΔleuD ΔpanCD (Bleupan) [19] encoding the Vibrio luxAB 9 
gene was used for infection and luminescence was measured as described [18] after 10 
cells lysis. Correlation between CFUs and luminescence was established before 11 
experiments. Experiments were carried out in sextuplicate. 12 
 13 
2.12. In vitro nanobiotics uptake by THP-1 cells  14 
THP-1 cells were plated on glass coverslips, infected with a mCherry fluorescent reporter 15 
strain of M. tuberculosis H37Rv ΔleuD ΔpanCD (Bleupan) [19] using a MOI of 10:1, and 16 
treated for 1h with Nano INH Cou-6 (to a final concentration of 50 nM Cou-6), rinsed with 17 
PBS, fixed with 4% formaldehyde, rinsed with water and then mounted with ProLong 18 
Gold antifade containing DAPI (Invitrogen). Images were acquired on a Zeiss 780 19 
confocal microscope (Plan-Apochromat × 63/1.40 Oil-immersion lens) and analysed with 20 
Zen 2010 (Carl Zeiss) and Fiji (open source).  21 
 22 
2.13. Zebrafish husbandry and ethic statements 23 
Experimental procedures were performed using the nacre line zebrafish. Transgenic 24 
Tg(mpeg:mCherryCAAX)sh378 zebrafish line was used to visualize macrophages 25 
chemotaxis towards injection sites. Zebrafish were raised and maintained according to 26 
standard protocols in UK Home Office-approved facilities in The Bateson Centre aquaria 27 
at the University of Sheffield under AWERB (Animal Welfare and Ethical Review Bodies). 28 
13 
 
Eggs were obtained from pairs of adult fish by natural spawning and raised at 28.5°C in 1 
tank water. All animal experiments described in the present study were conducted on 2 
the Project Licence P1A4A7A5E held by Professor Stephen Renshaw at the University 3 
of Sheffield. 4 
 5 
2.14. In vivo mycobacterial infection and treatment  6 
M. marinum strain M carrying pTEC27 (Addgene, plasmid 30182) that express red 7 
fluorescent protein (tdTomato) were grown at 28.5 °C under hygromycin B selection in 8 
Middlebrook 7H9 broth medium supplemented with oleic acid, albumin, dextrose, 9 
catalase (OADC) enrichment and 0.05% Tween 80 (7H9OADC/T).  Mid‐log‐phase cultures 10 
of M. marinum expressing tdTomato were pelleted, washed twice and resuspended in 11 
PBS Tween (PBST). Mycobacterial suspensions were then homogenized through a 26‐12 
gauge needle and adjusted to an optical density at 600 nm (OD600) of 1 in PBST and 13 
mixed with phenol red.  14 
Microinjections of 2 nL of bacterial suspensions of known concentration (containing 15 
around 150 mycobacteria) were carried out directly into the caudal vein in 30 hpf 16 
embryos previously dechorionated and 0.02% w/v tricaine-anesthetized. The inoculum 17 
size was checked by injection of 2 nL in sterile PBST and plated on 7H10OADC agar. 18 
Infected embryos were then transferred into plates and incubated at 28.5 °C.  19 
At 4 h post-infection, either free antibiotics or nanobiotics of known concentrations were 20 
intravenously administered to embryos. Groups of infected/treated embryos were then 21 
transferred into 6‐well plates and incubated at 28.5 °C. To determine efficiency of 22 
nanodrugs vs free drugs on infection outcomes, embryos were collected at 3 days post 23 
infection/treatment and imaged for both granuloma quantification (defined at least 10 24 
infected cells) and bacterial burdens analysis as Fluorescent Pixel Count (FPC) by 25 
fluorescence microscopy.  26 
 27 
2.15. Macrophages recruitment observation 28 
14 
 
Macrophage mobilization towards nanobiotic-injected sites was elicited through injection 1 
of Cou-6-labelled Nano Blank into the muscle compartment of 3 days post-fertilization 2 
transgenic larvae Tg(mpeg1:mCherry-CAAX)sh378 [21]. Leucocytes chemotaxis was 3 
visualized and imaged at 1 and 4 h post-injection using confocal microscopy. 4 
 5 
2.16. Epifluorescence, confocal microscopy and imaging  6 
Epifluorescence microscopy was performed using a Leica MZ10 F stereomicroscope 7 
(Leica Microsystems, Germany) equipped with GXCAM-U3 Series 5MP (GT Vision) 8 
camera. Confocal microscopy was performed using a Leica TCS-SPE confocal DMi8 9 
inverted microscope (Leica Microsystems, Germany) using a HC FL PLAB 10x/0.40, 20x 10 
or 40x objective lenses and captured using a Hammamatsu ORCA-Flash 4.0 camera 11 
(Hammamatsu, Japan).    12 
 13 
2.17. Statistical analysis 14 
All data are expressed as mean ± SEM. Statistical analysis for comparing two 15 
experimental groups was performed using two-sided Student’s t-tests. A value of 16 
P < 0.05 was considered statistically significant. Analyses were performed with Prism 7 17 
(Graph pad Software). Differences are labelled n.s. for not significant, * for P ≤ 0.05, ** 18 
for P ≤ 0.01, *** for P ≤ 0.001 and **** for P ≤ 0.0001. The sample size of each experiment 19 
was determined to be the minimal necessary for statistical significance by the common 20 
practice in the field. No animals were excluded from the experiments. 21 
 22 
3. Results and discussion 23 
 24 
3.1. Synthesis and characterization of isoniazid-based polymer 25 
15 
 
Both blank and INH-based polymers were characterized by Fourier-transformed infrared 1 
spectroscopy (FTIR) (Fig. 2a) and 1H nuclear magnetic resonance (NMR; Fig. 2b). The 2 
characteristic FTIR peaks from the α-keto polyester blank polymer appear at 2933 and 3 
2856 cm−1 due to C−H stretching vibrations from CH2 and CH3 functional groups, at 1271 4 
and 1179 cm−1 due to C−O stretching from ester groups, and at 683 cm−1 due to C−C=O 5 
bending. The INH drug has a characteristic peak at 3303 cm−1, related to N−H stretching 6 
of the hydrazide group, which shifts to 3255 cm−1 and reduces in intensity upon formation 7 
of the hydrazone bond during conjugation to the polymer [22]. In addition, INH-polymer 8 
conjugation also generates peaks at 1556 cm−1 (from H−N−N bending), at 1136 cm-1 9 
(from N−N stretching of the hydrazide group), and at 841 cm−1 (from ring C−C−H bending 10 
vibrations). The peaks in the region of 3100-2900 cm−1 characteristic from C−H 11 
stretching vibrations of heteroaromatic compounds, present in the INH spectrum, are too 12 
weak to observe following polymer incorporation. Bands at 3105 cm−1, 1633 cm−1 and 13 
1321 cm−1 generated from stretching and bending vibrations of the NH2 group are 14 
present in the INH spectrum, disappear from the INH polymer spectrum, corroborating 15 
the formation of the hydrazone bond. The peaks at 1663 cm−1 (for INH), 1721 cm−1 (for 16 
the blank polymer), and 1685 cm−1 (for the INH polymer) correspond to C=O stretching 17 
of several carbonyl groups.  18 
The 1H-NMR spectra of the blank (Fig. S1; chemical shifts reported in Supplementary 19 
Information) and INH (Fig. 2b; chemical shifts reported in Supplementary 20 
Information) polymers in DMSO-d6 confirmed our predicted structure. The spectrum of 21 
the blank polymer shows the presence of peaks at 2.53−2.56 ppm and 3.04−3.07 ppm 22 
from the protons of the ketoglutarate unit and peaks between 1.26 ppm and 1.67 ppm 23 
attributed to the aliphatic protons of the octanediol unit. Protons α to the backbone ester 24 
group on the octanediol unit produced peaks at 3.97−4.00 ppm and 4.16−4.19 ppm (Fig. 25 
S1). The INH polymer spectrum shows new peaks at 7.69−7.73 and 8.71−8.78 ppm 26 
attributed to the aromatic protons of INH.  The integration ratio of INH aromatic protons 27 
16 
 
to polymer chain protons indicated complete conjugation of the INH to the polymer. The 1 
integration ratio of protons from the methyl ester end-groups to protons on the repeating 2 
unit indicates a polymer chain with an average of 16 and 18 repeating units, equivalent 3 
to a Mn of 4,147 g/mol for the blank polymer and a Mn of 6,804 g/mol for INH polymer, 4 




Fig. 2. Characterization of polymer-drug conjugates. a. FTIR spectra of INH (top), Blank 1 
Polymer (middle), and INH Polymer (Bottom). b. 1H-NMR spectrum of INH Polymer in 2 
DMSO-d6 and peak assignments.  3 
 4 
3.2. Formulation and characterization of nanobiotics and in vitro drug release 5 
Nanoparticles were generated from both blank and INH-conjugated polymers using 6 
single-emulsion solvent evaporation [23], which we visualized in their native solutions  7 
using Cryo-EM [24, 25] (Fig. 3a). Nanoparticles formulated from blank polymer were 8 
irregular in shape and presented crystalline visual appearance with regular shaded 9 
patterns (consistent with the semi-crystalline nature of many polyesters [26]) while those 10 
made from INH polymer were perfectly spherical (reportedly favouring uptake by 11 
phagocytes [27]), densely packed, and presented amorphous visual appearance, 12 
possibly due to an increase in disordered regions due to the presence  of the bulky pyridyl 13 
ring after drug conjugation [28]. Using Dynamic Light Scattering (Fig. 3b), we found that, 14 
compared to blank nanoparticles, INH nanobiotics were slightly smaller (Z-average of 15 
284 ± 11 nm compared to 392 ± 75 nm), had similar polydispersity index (0.321 16 
compared to 0.344), and had less negative zeta potentials (-20 ± 3 mV compared to -31 17 
± 5 mV; consistent with the presence of basic functional groups). INH loading in the 18 
nanobiotics was 25 ± 5 % wt (g INH/g nanobiotic), higher than 16% wt reported for INH-19 
chitosan conjugates [13] and 30 times higher than the 0.8% wt (7.78 mg/g) reported for 20 
other INH conjugated polyesters, such as PLGA [15].  21 
We next examined the drug release properties of INH nanobiotics in vitro (Fig. 3c). As 22 
expected from the hydrolytic cleavage of the hydrazone bond, greater and more rapid 23 
INH release was observed during incubation at acidic pH levels that replicate those 24 




Fig. 3. Characterization of polymeric nanobiotics a. Cryo-EM images show different 2 
shape and crystallinity of the Blank (left) and INH (right) nanobiotics (scale bar, 100 nm). 3 
b. Size distribution (nm) and zeta potential (mV) of Blank (blue) and INH (red) polymeric 4 
nanobiotics formulated by single emulsion solvent evaporation technique (n=3). c. INH 5 
release from Nano INH at pH 5 (blue), 6 (red), and 7.4 (green), mimicking the acidic 6 
conditions of the phagolysosome and physiological conditions of systemic circulation 7 
(n=3).  8 
 9 
3.3. In vitro evaluation of INH nanobiotics in Mtb-infected human primary 10 
macrophages and THP-1 cells 11 
We hypothesized that nanobiotics would be successfully targeted to infecting Mtb since, 12 
following internalization by phagocytes, they would be targeted directly to intracellular 13 
mycobacteria, through endosomal fusion [31], and delivered to extracellular 14 
19 
 
mycobacteria in granuloma or cords through the frequent trafficking of macrophages and 1 
neutrophils to these sites [32-34]. 2 
To investigate uptake by human cells, we incubated peripheral blood samples from 3 
healthy subjects with fluorescently-labelled INH nanobiotics. Using flow cytometry, we 4 
observed rapid high-level accumulation in all monocytes and neutrophils, as well as less 5 
efficient uptake by B and T cells (Fig. 4a). We also monitored internalization by Mtb-6 
infected cells using confocal microscopy (Fig. 4b; Supplementary Movie). Nanobiotics 7 
were avidly taken up by macrophage cell lines and trafficked to internal compartments 8 
including mycobacteria-containing phagosomes. We then confirmed that INH 9 
nanobiotics were active against intracellular Mtb, showing equivalent potency to free INH 10 
when added to infected THP-1 cells and primary human macrophages (Fig. 4c; 11 
Supplementary Figure S2). 12 
 13 
 14 
Fig. 4. Nanobiotic uptake by phagocytic cells and in vitro efficacy against M. tuberculosis. 15 
a. Nanobiotics uptake by white blood cells quantified by fluorescence-activated cell 16 
sorting (FACS). Coumarin 6-labelled Nano INH are preferentially uptaken by phagocytic 17 
cells, namely monocytes (CD14+) and neutrophils (CD15+), rather than lymphocytes, 18 
such as T cells (CD3+) and B cells (CD19+), likely reflecting their large size distribution.  19 
b. Confocal microscopy images of differentiated THP-1 cells infected with a mCherry 20 
20 
 
fluorescent reporter strain of M. tuberculosis H37Rv ΔleuD ΔpanCD (red) and treated 1 
with Cou-6-labelled Nano INH (green) (scale bar, 10 µm) c. Differentiated THP-1 cells 2 
were infected with a luminescent reporter strain M. tuberculosis H37Rv ΔleuD ΔpanCD, 3 
treated with 100 µM INH either as a free drug or as nanodrug and intracellular M. 4 
tuberculosis was assessed 48h post-infection by relative luminescence units (RLUs). 5 
Untreated cells and cells treated with drug-free nanobiotics (Nano Blank) were used as 6 
negative controls. Results are presented in terms of RLUs normalized to untreated cells 7 
(Mean ± SEM, n = 6).   8 
 9 
3.4. Pre-clinical studies in a zebrafish larval model of mycobacterial infection 10 
We proceeded to examine the fate and activity of nanobiotics in vivo by exploiting the 11 
optical transparency of zebrafish larvae. Nanoparticles were rapidly engulfed by 12 
macrophages following intramuscular injection (Figure 5a) and, in fish infected with M. 13 
marinum (a pathogenic mycobacterial species closely related to Mtb), nanoparticles 14 
were taken up by over 70% of all infected macrophages (Figure 5b & c). By 3 days post 15 
infection, we observed delivery of nanoparticles, presumably by macrophages, to both 16 





Fig. 5. In vivo testing of multi-drug nanobiotics in a M. marinum-infected zebrafish larval 2 
model. a. Confocal microscopy images showing nanobiotics-induced macrophage 3 
mobilization in vivo. Suspension of coumarin 6-labelled Nano Blank (green) was injected 4 
into the muscle of 3 dpf Tg(mpeg1:mCherryCAAX)sh378 zebrafish line harbouring red 5 
macrophages. Macrophage chemotaxis towards injection site has been monitored at 1 6 
and 4 h post injection (scale bar, 20 µm). b. Quantification and c. Confocal imaging of 7 
coumarin 6-labelled Nano Blank (green) uptake by M. marinum-infected macrophages 8 
(red) after 4 h post infection (scale bar, 1 µm). d. Confocal imaging showing the 9 
repartition and accumulation of coumarin 6-labelled Nano Blank (green) into a M. 10 
marinum (red)-granuloma (left, scale bar, 5 µm) and a mycobacterial cord structure (right, 11 




We next explored the potential application of nanobiotics for synchronous delivery of 1 
multiple drugs and successfully encapsulated CFZ within INH-nanobiotics (Nano INH & 2 
CFZ), with a drug loading of 22 ± 1 % wt (g CFZ/g nanobiotic), and these remained 3 
structurally stable in solution for 9 months at room temperature (Supplementary Figure 4 
S3).  5 
Zebrafish larvae were then infected with M. marinum and, 4 h later, treated with either 6 
free drug (INH alone or INH with CFZ) or injected with nanobiotics (Nano INH, Nano INH 7 
& CFZ, or blank nanoparticles). At 3 days post infection, both INH- and INH & CFZ- 8 
nanobiotics, but not the equivalent concentration of free drugs, were able to significantly 9 
reduce bacterial burden and granuloma number in M. marinum-infected fish compared 10 
to controls (Fig. 6 a-c). 11 
 12 
 13 
Fig. 6. Effect of nanobiotics at 3 days post infection on zebrafish infected with 14 
fluorescently-labelled M. marinum. a. representative images (scale bar, 200 µm). b. 15 
quantification of bacterial load (results plotted as mean ± SEM from 2 independent 16 
experiments; n=21). c. Quantification of granuloma number at 3dpi. Results are plotted 17 
as mean ± SEM from 2 independent experiments (n=19). 18 
23 
 
Due to the wide-ranging tools and strains available, the mouse infection model has been 1 
the most extensively studied in Mtb research. However, the main disadvantage of this 2 
model is the inability of mice to effectively replicate human pathologies, such as the 3 
caseous granuloma formation. Instead, mice form diffuse and noncaseating lesions, 4 
likely due to the fact that Mtb is not a natural pathogen of mice. Other mammalian 5 
models, such as guinea pigs and rabbits, which produce necrotic granulomas and more 6 
closely resemble the human Mtb pathology, are not as amenable for transgenic and 7 
knockout line production. The primate infection model (e.g. macaques) is perhaps the 8 
most clinically relevant, but it is limited by high costs and ethical restrictions [35, 36].  9 
In recent years, zebrafish has been recognised as a useful vertebrate animal model, 10 
particularly due to its low cost, ease of manipulation and optical transparency, which 11 
allows non-invasive and real-time monitoring using imaging tools of host-pathogen 12 
interactions at a cellular level in a live animal [37]. Despite mammal models being 13 
evolutionary more similar to humans, zebrafish and human genomes present high 14 
homology (71% of human protein-encoding genes and 82% of disease related genes 15 
have zebrafish orthologues), with functional domains of proteins being almost identical 16 
in both species [38]. The zebrafish-M. marinum model also presents pharmacological 17 
similarities (i.e. similar effect of drugs) and homologous immune responses to humans, 18 
including robust granuloma formation [35, 36]. This model is not, of course, intended to 19 
replace mammalian infection models, but is rather an unique and powerful tool for 20 
phenotypic screenings and to study pathophysiological events.  21 
 22 
4. Conclusions 23 
We report a smart multi-drug delivery vehicle, which allows the simultaneous 24 
incorporation of both hydrophilic and hydrophobic drugs at high concentrations and their 25 
targeted delivery to both intracellular and granuloma-resident mycobacteria in vivo. The 26 
24 
 
main advantage of this system is the synthetic simplicity and versatility. The drug is 1 
directly conjugated to the polymer without the need for any further chemical 2 
modifications. The drug-polymer bond is acid-labile, allowing site-specific drug release, 3 
and the polymer itself is hydrolysable facilitating excretion. Polymer size can be tuned 4 
without affecting the high drug loading capacity, since there is one drug conjugation site 5 
per monomeric unit of polymer. With the slow development of new antibiotics, tunable 6 
polymeric nanobiotics have the potential to deliver more effective and more tolerable 7 
combination chemotherapy using existing drugs for Mtb and other infectious diseases.   8 
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Supplementary Information 1 
NMR Chemical Shifts 2 
Blank Polymer 3 
1H-NMR (500 MHz, DMSO-d6): δ 4.17 (t, J = 15 Hz, 2H), δ 3.98 (t, J = 15 Hz, 2H), δ 3.06 4 
(t, J = 15 Hz, 2H), δ 2.55 (t, J = 15 Hz, 2H), δ 1.65 (t, J = 15 Hz, 2H), δ 1.54 (t, J = 15 5 
Hz, 2H), δ 1.31-1.26 (m, 8H) 6 
 7 
INH Polymer 8 
1H-NMR (500 MHz, DMSO-d6): δ 8.78-8.71 (br, 2H), δ 7.73-7.69 (br, 2H), δ 4.30-4.13 9 
(br, 2H), δ 3.97 (br, 2H), δ 2.89-2.79 (br, 2H), δ 2.59 (br, 2H), δ 1.64 (br, 2H), δ 1.51 (br, 10 
2H), δ 1.22 (br, 8H) 11 
 12 
 13 





Figure S2. Human primary macrophages were infected with M. tuberculosis H37Rv 3 
ΔleuD ΔpanCD, treated with 10 µM INH either as a free drug or as nanodrug and viable 4 
intracellular M. tuberculosis was assessed 48h post-infection by colony-forming units 5 
(CFUs). Untreated cells and cells treated with drug-free nanobiotics (Nano Blank) were 6 
used as negative controls. Results are presented in terms of CFUs normalized to 7 





Figure S3. Cryo-EM images of freshly synthesized (a) and 9 months old (b) INH & CFZ 2 
nanobiotics stored at room temperature show the long-term physical stability of the 3 
nanobiotics (scale bar, 200 nm for top left image and 1 µm for all others). 4 
 5 
 6 
